NIHR Bulletin

NIHR News

New vision for harnessing the full potential of data-enabled trials published

NIHR blog: Improving the uptake of research findings in global health

 

Forthcoming COVID-19 funding call: Community-based COVID-19 platform study for novel antivirals
The NIHR is intending to open a funding call on behalf of the DHSC Antivirals Taskforce, for a team to set up and run a community-based clinical trial platform for novel therapeutic candidates in the UK. The Taskforce was set up to find effective and safe treatments for COVID-19, and will identify and prioritise potential candidates for this study. The study team will be expected to quickly set up a clinical trial platform to evaluate these novel candidates, and start recruiting patients into the platform in Autumn 2021.

The likely advert date for this topic is 19 July 2021. However, please note this is an indicative date, which may change.

 

Funding Opportunities

Latest NIHR funding calls

Harkness Fellowships in Health Care Policy and Practice

Efficacy and Mechanism Evaluation (EME) Programme
21/529 Efficacy trials in regenerative medicine

Public Health Research (PHR) Programme
21/525 Permitted Developments Rights
21/527 Development Award – Local authority-level research priorities on climate change
21/530 Application Development Award – Healthy extended working lives

Policy Research Programme (PRP)
Mental health services funding call

 

Your local branch of the NIHR RDS (Research Design Service) is based within the BU Clinical Research Unit (BUCRU) should you need help with your application. We advise on all aspects of developing an application and can review application drafts as well as put them to a mock funding panel (run by RDS South West) known as Project Review Committee, which is a fantastic opportunity for researchers to obtain a critical review of a proposed grant application before this is sent to a funding body.

Contact us as early as possible to benefit fully from the advice

Feel free to call us on 01202 961939 or send us an email.